Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with heart failure for at least 90 days and are currently experiencing moderate symptoms (not the most mild, but not the most severe)
- People who, in the past year, were admitted to hospital with worsening heart failure as the main reason for admission
- OR people who had an unplanned outpatient visit in the past 6 months where their water tablet (diuretic) dose was significantly increased, or they received diuretics through a drip, or had fluid removed by a medical procedure for worsening heart failure
- OR people who had a specific heart-related blood test (NT-proBNP or BNP) result above a certain level in the past 3 months — the exact level required depends on the person's heart pump function and heart rhythm (confirm with trial site)
- People who are able to understand what the study involves
- People who are willing to sign a consent form agreeing to take part
- People who are able and willing to attend follow-up appointments at the study site and by phone
- People who are able and willing to use a specific remote heart monitoring device called the CardioMessenger, and who accept the BIOTRONIK Home Monitoring system
Who may not be able to join:
- People who already have a pacemaker, implantable defibrillator (ICD), cardiac resynchronisation therapy (CRT) device, or implantable cardiac monitor
- People for whom current medical guidelines strongly recommend implanting one of those devices
- People with a permanent or long-standing persistent irregular heart rhythm called atrial fibrillation (AF)
- People who have had a stroke, heart attack, or certain heart procedures (coronary stenting or bypass surgery) within the past 3 months
- People who are currently on ongoing kidney dialysis or peritoneal dialysis
- People who have complex congenital heart disease (a heart condition present from birth that is structurally complicated)
- People who are currently receiving chemotherapy, immunotherapy, or radiation therapy for active cancer
- People whose life expectancy is estimated to be less than one year
- People under 18 years of age
- People who are already taking part in another device or drug trial that could interfere with this study or affect its results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thorsten Lewalter, Prof. Dr., Biotronik SE & Co. KG
Phone: +49 (0) 30 68905 1182
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Heart failure events confirmed by WHF Adjudication Committee; Arrhythmias and subsequent therapeutic interventions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.